Marinus Pharmaceuticals announces NMPA approval of Ganaxolone for CDKL5 deficiency disorder
Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a leader in developing innovative therapeutics for seizure disorders, has achieved a significant milestone with the approval of its ganaxolone oral ... Read More
Antengene’s XPOVIO approved in China for diffuse large B-cell lymphoma
Antengene Corporation Limited, a commercial-stage global biopharmaceutical company, has announced a significant milestone with the China National Medical Products Administration (NMPA) approving a new indication ... Read More